CN113939316A - 细胞竞争调控剂 - Google Patents

细胞竞争调控剂 Download PDF

Info

Publication number
CN113939316A
CN113939316A CN202080039611.0A CN202080039611A CN113939316A CN 113939316 A CN113939316 A CN 113939316A CN 202080039611 A CN202080039611 A CN 202080039611A CN 113939316 A CN113939316 A CN 113939316A
Authority
CN
China
Prior art keywords
cells
protein
cell
lilrb3
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080039611.0A
Other languages
English (en)
Chinese (zh)
Inventor
丸山刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Waseda University
Original Assignee
Waseda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waseda University filed Critical Waseda University
Publication of CN113939316A publication Critical patent/CN113939316A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080039611.0A 2019-03-28 2020-03-30 细胞竞争调控剂 Pending CN113939316A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019063594 2019-03-28
JP2019-063594 2019-03-28
JP2019-069777 2019-04-01
JP2019069777 2019-04-01
PCT/JP2020/014715 WO2020196926A1 (ja) 2019-03-28 2020-03-30 細胞競合の制御剤

Publications (1)

Publication Number Publication Date
CN113939316A true CN113939316A (zh) 2022-01-14

Family

ID=72609511

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080039611.0A Pending CN113939316A (zh) 2019-03-28 2020-03-30 细胞竞争调控剂

Country Status (5)

Country Link
US (1) US20220233638A1 (https=)
EP (1) EP3949993A4 (https=)
JP (1) JP7696617B2 (https=)
CN (1) CN113939316A (https=)
WO (1) WO2020196926A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024219474A1 (ja) * 2023-04-21 2024-10-24 株式会社Logomix Ｋｉｒ遺伝子クラスター領域、ｌｉｌｒ遺伝子クラスター領域およびｋｌｒ遺伝子クラスター領域のいずれか１以上の領域において欠失を有する細胞およびその製造方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517330A (ja) * 2010-01-20 2013-05-16 トーラックス インコーポレイテッド 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片
US20150174203A1 (en) * 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
WO2018022881A2 (en) * 2016-07-29 2018-02-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
JP2018510340A (ja) * 2015-03-06 2018-04-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 抗ｌｉｌｒｂ抗体ならびにがんの検出及び処置におけるその使用
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
US20180251558A1 (en) * 2014-10-24 2018-09-06 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
US20070281327A1 (en) 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
EP2854723B1 (en) 2012-05-25 2017-07-19 Coloplast A/S Comfort layer for a collecting bag
JP6188244B2 (ja) 2012-12-27 2017-08-30 テイ・エス テック株式会社 シート装置
CN111867614A (zh) * 2018-01-18 2020-10-30 艾达奈特公司 抗lilrb抗体及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517330A (ja) * 2010-01-20 2013-05-16 トーラックス インコーポレイテッド 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片
US20150174203A1 (en) * 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
US20180251558A1 (en) * 2014-10-24 2018-09-06 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
JP2018510340A (ja) * 2015-03-06 2018-04-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 抗ｌｉｌｒｂ抗体ならびにがんの検出及び処置におけるその使用
WO2018022881A2 (en) * 2016-07-29 2018-02-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"leukocyte immunoglobulin-like receptor subfamily B member 3 isoform X4 [Canis lupusfamiliaris]" *
"MHC class I DLA-88 precursor [Canis lupus familiaris]" *
KATHARINA PFISTERSHAMMER ET AL.: "Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients", 《BLOOD》 *
SURYAPRAKASH R. SAMBHARA ET AL.: "Programmed Cell Death of T Cells Signaled by the T Cell Receptor and the α3 Domain of Class I MHC", 《SCIENCE》 *
石银 等: "HIV-1 逃逸HLA限制性细胞毒性T淋巴细胞应答的研究进展", 病毒学报 *

Also Published As

Publication number Publication date
JP7696617B2 (ja) 2025-06-23
EP3949993A4 (en) 2023-07-05
US20220233638A1 (en) 2022-07-28
EP3949993A1 (en) 2022-02-09
JPWO2020196926A1 (https=) 2020-10-01
WO2020196926A1 (ja) 2020-10-01

Similar Documents

Publication Publication Date Title
JP7186196B2 (ja) 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法
Minetti et al. Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency
JP2021516996A (ja) 生物学的に関連する直交サイトカイン／受容体対
KR102940898B1 (ko) 대식세포 분화 및 면역의 변형 방법
JP2019531056A (ja) 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
TW202330019A (zh) 用於治療自體免疫疾病及癌症之組成物及方法
WO2017134116A1 (en) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
EP2413968B1 (en) Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses
US20190055560A1 (en) Fats as a target for treating tumors and uses thereof
KR20190028664A (ko) 암의 치료를 위한 면역 체크포인트 억제제와 세포독성 t 세포
RU2727900C2 (ru) Фармацевтическая композиция для предотвращения или лечения заболеваний, опосредованных регуляторными т-клетками
JPWO2014126127A1 (ja) ネクロプトーシス関連疾患の治療用医薬組成物及びその有効成分のスクリーニング方法
US20210000921A1 (en) Methods and compositions for modulating thymic function
US20220096551A1 (en) Combinations, nanoparticles and methods for controlling natural killer cell activation and function
JP7696617B2 (ja) 細胞競合の制御剤
CN110709508A (zh) 治疗新生性疾病的方法
WO2022104056A2 (en) Modulating bhlhe40 in the differentiation of type 1 regulatory t cells and controlling t cell exhaustion
US20250297310A1 (en) Hematopoietic loss of y chromosome leads to cardiac fibrosis and dysfunction and is associated with death due to heart failure
KR102352127B1 (ko) Mitf 억제제를 유효성분으로 함유하는 골수-유래 억제세포 저해용 조성물
JP2021523098A (ja) Ｔ細胞による認識を強化するよう抗原性を調節する方法
Wang et al. CTLA-4 nanovesicles disrupt dendritic cell-driven CD8 T cell priming for myocardial infarction therapy
US20230107770A1 (en) Method of enhancing immunotherapy using er stress pathway inhibitors
KR20230037574A (ko) 키메라 항원 수용체 강직성 신호전달을 감소시키기 위한 방법 및 조성물
US20230338423A1 (en) Targetable immune checkpoint for immunotherapy
US20250213687A1 (en) Therapeutic t cell product

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220114

WD01 Invention patent application deemed withdrawn after publication